

Xiaoyan Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/28071/publications.pdf>

Version: 2024-02-01

42
papers

683
citations

623574

14
h-index

642610

23
g-index

47
all docs

47
docs citations

47
times ranked

1131
citing authors

#	ARTICLE	IF	CITATIONS
1	Qualitative and quantitative proteomic and metaproteomic analyses of healthy human urine sediment. <i>Proteomics - Clinical Applications</i> , 2022, 16, e2100007.	0.8	2
2	Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 219-227.	0.8	19
3	96DRA-Urine: A high throughput sample preparation method for urinary proteome analysis. <i>Journal of Proteomics</i> , 2022, 257, 104529.	1.2	2
4	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. <i>Thoracic Cancer</i> , 2022, 13, 412-422.	0.8	19
5	Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 879554.	1.3	0
6	Analysis of the saliva metabolic signature in patients with primary Sjögren's syndrome. <i>PLoS ONE</i> , 2022, 17, e0269275.	1.1	9
7	Urine metabolites for preoperative prediction of acute kidney injury after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, , .	0.4	4
8	A qualitative and quantitative analysis of the human gingival crevicular fluid proteome and metaproteome. <i>Proteomics</i> , 2021, 21, e2000321.	1.3	5
9	Proteome Characterization of Glaucoma Aqueous Humor. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100117.	2.5	7
10	Aqueous humor proteomic analysis of acute angle-closure glaucoma with visual field loss. <i>Annals of Translational Medicine</i> , 2021, 9, 0-0.	0.7	1
11	Risk factors for immune-related adverse events: what have we learned and what lies ahead?. <i>Biomarker Research</i> , 2021, 9, 79.	2.8	36
12	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 749461.	2.2	11
13	Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. <i>Translational Lung Cancer Research</i> , 2021, 10, 4477-4493.	1.3	14
14	A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma. <i>International Urology and Nephrology</i> , 2020, 52, 437-446.	0.6	13
15	Clinicopathological characteristics of lung cancer in patients with systemic sclerosis. <i>Clinical Respiratory Journal</i> , 2020, 14, 1131-1136.	0.6	6
16	Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker. <i>Frontiers in Oncology</i> , 2020, 10, 1507.	1.3	7
17	Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer. <i>ESMO Open</i> , 2020, 5, e000823.	2.0	11
18	Proteomic Study of Aqueous Humor and Its Application in the Treatment of Neovascular Glaucoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 587677.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Urinary protein biomarkers for pediatric medulloblastoma. <i>Journal of Proteomics</i> , 2020, 225, 103832.	1.2	10
20	LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 717.	1.3	31
21	LC-MS-based urine metabolomics analyses for early diagnosis of medulloblastoma. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
22	Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC. <i>Frontiers in Oncology</i> , 2019, 9, 663.	1.3	32
23	Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib. <i>Cancer Management and Research</i> , 2019, Volume 11, 8191-8200.	0.9	4
24	Evaluation of Urinary Proteome Library Generation Methods on Data-Independent Acquisition MS Analysis and its Application in Normal Urinary Proteome Analysis. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800152.	0.8	7
25	Comprehensive Analysis of Individual Variation in the Urinary Proteome Revealed Significant Gender Differences. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1110-1122.	2.5	50
26	Urinary metabolic variation analysis during pregnancy and application in Gestational Diabetes Mellitus and spontaneous abortion biomarker discovery. <i>Scientific Reports</i> , 2019, 9, 2605.	1.6	22
27	UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 1195.	1.1	19
28	Association of PFS with levels of pretreatment lactate dehydrogenase in patients with EML4-ALK rearrangement non-small cell lung cancer treated with ALK tyrosine kinase inhibitor.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20513-e20513.	0.8	0
29	Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery. <i>International Journal of Cancer</i> , 2018, 143, 408-418.	2.3	59
30	PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. <i>Future Oncology</i> , 2018, 14, 665-674.	1.1	49
31	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6189-6196.	1.0	47
32	Clinicopathological features of lung cancer in patients with rheumatoid arthritis. <i>Journal of Thoracic Disease</i> , 2018, 10, 3965-3972.	0.6	9
33	Comparative proteomic analysis of the influence of gender and acid stimulation on normal human saliva using LC/MS/MS. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600142.	0.8	13
34	Differential proteome analysis of hippocampus and temporal cortex using label-free based 2D-LC-MS/MS. <i>Journal of Proteomics</i> , 2017, 165, 26-34.	1.2	8
35	Comprehensive Map and Functional Annotation of Human Pituitary and Thyroid Proteome. <i>Journal of Proteome Research</i> , 2017, 16, 2680-2691.	1.8	27
36	Primary cutaneous aspergillosis caused by <i>Aspergillus.fumigatus</i> in an immunocompetent patient. <i>Medicine (United States)</i> , 2017, 96, e8916.	0.4	14

#	ARTICLE	IF	CITATIONS
37	Mitral regurgitation after anthracycline-based chemotherapy in an adult patient with breast cancer. <i>Medicine (United States)</i> , 2017, 96, e9004.	0.4	5
38	Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?. <i>Oncotarget</i> , 2017, 8, 86969-86984.	0.8	5
39	Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, 9, 2911.	1.0	18
40	TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 20977-20992.	0.8	42
41	Dermatopontin promotes adhesion, spreading and migration of cardiac fibroblasts in vitro. <i>Matrix Biology</i> , 2013, 32, 23-31.	1.5	25
42	Characterization of LC-MS based urine metabolomics in healthy children and adults. <i>PeerJ</i> , 0, 10, e13545.	0.9	2